Post by Biotech & Investment Insights

💸 $3B+ in biotech, medtech & healthtech funding this week. From RNA editing to longevity medicines to kidney disease therapies: here’s what happened 👇 🧬 Ascidian Therapeutics signed a research and licensing deal with Eli Lilly and Company worth up to $1.9B to develop RNA exon editing therapies for inherited kidney diseases. 🩺 Everest Medicines licensed a BTK inhibitor to Travere Therapeutics in a deal worth up to $1.14B+, including $112.5M upfront and up to $1.03B in milestones. ⏳ NewLimit raised $435M Series C led by Founders Fund. The company plans to bring its first age-reprogramming therapy into human trials next year. 👨‍⚕️ Contraline secured $92.5M Series B co-led by BVF Partners and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus and others. The financing supports Phase 3 development of its reversible male contraceptive Gel. 🎯 ONA Therapeutics closed an oversubscribed $86.6M Series B co-led by Columbus Venture Partners and Merieux Equity Partners. Funds will advance its first-in-class ADC programs for breast and colorectal cancer. 🧠 CereVasc raised an oversubscribed $85M Series C led by Piper Sandler, with participation from Johnson & Johnson Innovation JJDC Inc, Medtronic, Bain Capital and others. The company is advancing its minimally invasive eShunt system for normal pressure hydrocephalus. 📸 Subtle Medical secured $33M, led by Morgan Stanley. The funding will expand its AI-powered imaging platform across MRI, PET and CT workflows. 🫀 Advanced NanoTherapies closed a $31M+ Series B, co-led by S3 Ventures and an undisclosed strategic investor. The company is advancing its dual-drug nanoparticle-coated balloon platform for vascular disease. 🏥 Semble raised a £30M Series C led by Revaia, with participation from Partech, Mercia Ventures and Octopus Ventures. The company will expand its AI-powered healthcare orchestration platform across the UK and Europe. 🎗️ Triomics raised a $22M Series B led by Battery Ventures, with participation from Nexus Venture Partners, Lightspeed, Y Combinator, Oncology Ventures and others. The company helps cancer centers use AI to manage clinical data and improve trial enrollment. 🤖 Waypoint Bio closed a $20M Series A led by Amplify Partners. The financing will advance its AI-designed in vivo CAR-T therapies for solid tumors. 👁️ Tavo Biotherapeutics raised a $17M Series A led by Pureos Bioventures. Funds will support development of novel therapies for glaucoma and retinal diseases. 🧠 ThIA Santé Mentale secured €5M from IRDI Capital Investissement and other investors to scale its coordinated psychiatry care platform. 💬 Which breakthrough caught your eye this week? 🔔 Want this recap in your feed every week? Follow us #biotech #medtech #healthtech #fundraising #VentureCapital #PrivateEquity